Microbiome Insights co-founder Dr. Brett Finlay to speak at Institut Pasteur event

Microbiome Insights co-founder and co-CSO Brett Finlay will be one of the distinguished speakers heading to Paris from October 15th to 16th 2018 for the Institut Pasteur meeting: Modeling the Mammalian Microbiota Host Superorganism, Current Tools and Challenges.

Knowledge about the role of microbiota and microbial metabolites in host functions and health has steadily increased over the past two decades. With mechanistic insights enabled by animal models and an increasing ability to characterize microbial communities during both development and adulthood, researchers are on the cusp of real therapeutic treatments. The Institut Pasteur meeting will bring together academic and industry leaders from this field to share new visions on host-microbiota mutualisms and parasitism, and to discuss the latest techniques and models. Along with Dr. Finlay, some exciting names on the program include Dr. Andrew Macpherson of Inselspital in Bern, Switzerland, giving the keynote address, and Marion Leclerc from the MICALIS Institute in Jouy-En-Josas, France and Philippe Sansonetti of Institut Pasteur.

Finlay will present his talk, entitled The Role of the Early Life Microbiota in Malnutrition and Environmental Enteropathy during the ‘Models of Pathogenesis’ session on Monday, October 15th. He has published over 500 papers and, as a principal investigator at the University of British Columbia he studies how microbes interact with hosts to influence health and disease. His lab developed the first animal model for the study of environmental enteropathy, a key feature of childhood malnutrition. Ongoing work with this model is now funded by the Gates Foundation in order to explore how it can better our understanding of the consequences of malnutrition. The Finlay lab also investigates the risks for childhood asthma stemming from microbiota and metabolic alterations during infancy, and were the first lab to demonstrate that early life intestinal microbiota plays a crucial role in asthma susceptibility.

By understanding how microbes colonize the small intestine and cause stunted growth and inflammation, Finlay and his collaborators hope to develop new nutritional therapies for human malnutrition. His lab’s work is essential for understanding the microbiota-host superorganism and the associations that are essential to maintain good health and development—making Finlay a “can’t miss” speaker at this prestigious meeting.

Microbiome Insights hosts students for educational laboratory tour

JUNE 15, 2018 — Microbiome Insights was pleased to welcome an enthusiastic group of post-secondary students from Vancouver’s Alexander College this week for a laboratory tour and presentation.

During the visit team member Ben Tantika, Senior Next-generation Sequencing Technician, described the cellular and molecular biology techniques used in research labs to answer scientific questions.

The second year biology students heard about the importance of knowing the ways in which biological sciences techniques can be applied in both research and industrial settings. Tantika also helped the students understand how a career in life sciences can take shape, giving anecdotes about his own previous experiences as an international student studying at UBC Okanagan.

 

Dr. Julian Davies speaks at celebration marking the opening of Microbiome Insights’ new lab facility

The Microbiome Insights team gathered with nearly 100 clients, friends, and supporters on May 28th for a champagne reception to celebrate the company’s continued growth and the opening of its new laboratory facility in the award-winning Pharmaceutical Sciences Building at the University of British Columbia (UBC). The event was topped off by remarks by the esteemed Dr. Julian Davies, UBC Professor Emeritus and chair of the External Scientific Board of the NIH Human Microbiome Project from 2009-2012.

In his speech, Davies gave a brief history of how the Human Microbiome Project came to be. He traced microbiome research up to the present day, saying: “Microbiome science is really getting going and I think it’s great that UBC has its own microbiome company. We should support them as strongly as possible.”

Company co-founders Drs. Brett Finlay and Bill Mohn were in attendance at the reception, along with Microbiome Insights clients, advisors, investors, granting agencies, and strategic collaborators.

CEO Malcolm Kendall said, “The microbiome is a really important area of science that is an important part of human, animal, plant and environmental health.” He emphasized that the company is not merely a service provider — but that the team members have a wealth of knowledge and are actively moving the science forward. “As we gain more understanding in this area we hope to be able to use microbiome derived products, tools, and services to enhance health and potentially cure or treat diseases,” he said.

Kendall also announced that Microbiome Insights hopes to foster the growing microbiome research community at UBC as a founding sponsor of the first annual UBC Microbiome Conference, to be held November 8 to 10, 2018.

The company hosted a microbiome poster competition alongside the reception, with winners receiving free sequencing services. Kevin Zhong, a postdoc at UBC’s Suttle Lab, received the top prize (50 free samples of amplicon sequencing); Peter Rahfeld and Spence Macdonald from Withers Lab received 2nd place (30 free samples of amplicon sequencing) and 3rd place (20 free samples of amplicon sequencing), respectively. The people’s choice award (a cash prize of $250) went to Peter Dobranowski of BCCHR.

See here for some photos from the event:

Dr. Julian Davies speaks with Microbiome Insights CEO Malcolm Kendall and guests; PHOTO CREDIT: Amer Abu-Khajil

Drinks table awaiting guest arrival; PHOTO CREDIT: Amer Abu-Khajil

Microbiome Insights co-founder Dr. Bill Mohn speaks with attendees; PHOTO CREDIT: Amer Abu-Khajil

Poster competition held in conjunction with the reception; PHOTO CREDIT: Amer Abu-Khajil

Remarks by Dr. Julian Davies; PHOTO CREDIT: Amer Abu-Khajil

Microbiome Insights co-founders, employees, and advisors; PHOTO CREDIT: Amer Abu-Khajil

PRESS RELEASE: Microbiome Insights, Global Leader in Microbiome Testing, Expands to New Lab Facilities on UBC Campus

Company’s rapid growth spurs move to new state-of-the-art facility

VANCOUVER, British Columbia–(BUSINESS WIRE)–Microbiome Insights, Inc. has announced the opening of its new laboratory on the campus of the University of British Columbia (UBC). The company, a leading end-to-end service provider for microbiome DNA sequencing and bioinformatic analysis, has expanded into its new state-of-the-art lab in order to meet the needs of over 100 clients.

“We have experienced rapid growth in our business and across the microbiome testing industry,” says CEO Malcolm Kendall. “This move is a major milestone for our company and helps us meet the needs of our growing client base, to deliver the high-quality service they have come to expect from us.”

Founded by two world-leading microbiome researchers, Drs. Brett Finlay and Bill Mohn of UBC, Microbiome Insights has grown rapidly since its incorporation in 2015—supporting over 200 microbiome studies across academia and industry. The new laboratory, located in the UBC Pharmaceutical Sciences Building, enables the company to expand its capacity, hire additional laboratory technicians and initiate clinical laboratory (CLIA) certification.

Brad Popovich, former Chief Scientific Officer at Genome British Columbia and Chair of Microbiome Insights’ Board of Directors, says, “The emergence of leading companies like Microbiome Insights is a sentinel for the growth of the microbiome testing marketplace; they are following a similar pattern of accelerated growth the field of genomics testing experienced over the past two decades.”

Microbiome Insights marked the opening of the new laboratory on May 28th with a reception and microbiome poster competition. Dr. Julian Davies, one of the scientists that spearheaded the NIH Human Microbiome Project (HMP) and Chair of the HMP External Scientific Board until 2015, spoke about the importance of microbiome research and the unique benefits of a UBC-based microbiome testing company.

See the original BusinessWire press release here.

Microbiome Insights to mark opening of new lab space with champagne reception and microbiome poster competition

Microbiome Insights, Inc. is planning to move operations into a new laboratory space in UBC’s Pharmaceutical Sciences building — and to mark the occasion, they will host a champagne reception with a poster competition open to local microbiome researchers.

Poster competition details:

The competition is open to all researchers and research assistants affiliated with UBC. Participants may bring any poster related to microbiome data collected within the past five years — up to 3 posters per participant may be entered.

Posters previously presented at academic conferences are encouraged! Most standard poster sizes can be accommodated.

Posters will be judged on both scientific content and presentation. Judges will award first, second, and third prizes as well as a “crowd favourite”.

DATE: Monday, May 28th, 2018

TIME: 4:00 pm to 6:00 pm

PLACE: Pharmaceutical Sciences Building, UBC Campus (2405 Wesbrook Mall, Vancouver, V6T 1Z3), Mezzanine floor

Participants should bring their poster for setup between 1:00 and 3:30 on May 28th. Winners will be announced during the champagne reception at 5:30.

Prizes are as follows:

First place: 50 free samples of amplicon sequencing ($5,500 value)
Second place: 30 free samples of amplicon sequencing ($3,300 value)
Third place: 20 free samples of amplicon sequencing ($2,200 value)
Crowd favourite: Cash prize of $250

RSVP for the poster competition to Jen Bower: jbower1023@gmail.com

Only the first 30 entries can be accepted, so email now!

Microbiome Insights included in list of BC’s top emerging life sciences companies

MARCH 14, 2018 — Microbiome Insights is honoured to be featured in the 2018 Emerging Rocket List by the management consulting firm Rocket Builders. The Emerging Rocket List is part of “Ready to Rocket”, a business recognition program that showcases British Columbia’s technology companies with the greatest potential for revenue growth as well as investment and market breakthrough.

The Ready to Rocket program encompasses 4 technology sectors: Information and Communications Technology, Cleantech, Life Science, and Digital Health. Microbiome Insights was one of the 10 companies included in the Emerging Rocket Life Science List, winning this recognition for the second year in a row.

Lists in the Ready to Rocket program are predictive of success; since 2003, the program has accurately identified future growth leaders in each category through rigorous sector and company analyses spanning several months.

To qualify as a candidate in the Life Science category, companies must have established industry relationships and must also be undergoing customer validation and regulatory approval. The selection committee assesses candidates based on early indicators of long-term potential and increasing shareholder value, such as passing key regulatory hurdles and achieving related validation steps.

“We identify companies that have both innovative technology and a fit within the industry value chain. Our analysis of the market and the company progress led to our selection of Microbiome Insights as a Ready to Rocket Life Science company,” said Thealzel Lee, Senior Partner, Rocket Builders.

PRESS RELEASE: Exploring the ‘second genome’ for new insights: Genome BC invests in local microbiome startup

DECEMBER 6, 2017 – As part of its Industry Innovation Program (I² Fund), Genome BC is investing CAD $750,000 in a local microbiome testing company—Vancouver-based Microbiome Insights (MBI), which provides next-generation-sequencing-based analytical testing and consulting services to microbiome researchers in academia and industry. The new funding adds to the company’s recent round of equity financing, which closed in October.

Microbiomes are the communities of microorganisms – including bacteria, viruses and fungi – that inhabit humans, animals, plants and other environments. These tiny universes perform diverse functions; microbiomes are critical to human health, affecting immune system function, vitamin and hormone synthesis, drug metabolism and energy harvest from the diet.

Detrimental changes to the human microbiome have been linked to allergies, asthma, colon cancer, C. difficile infections, diabetes, inflammatory bowel disease, obesity, neurodevelopment and neurodegenerative disease and many other diseases. Genomic tools are yielding a growing body of knowledge about these links, paving the way for new opportunities to develop microbiome-based clinical grade diagnostics and therapeutics.

Malcolm Kendall, CEO of Microbiome Insights, says, “The explosive growth in microbiome research – given its fundamental importance to human, animal, plant and environmental health – has significantly outpaced existing capacity to provide microbiome testing, especially outside of academia. The building of this new industry is a unique market opportunity.”

“At Microbiome Insights, our ability to advance innovation through microbiome analysis is borne out by our rapid growth and expanding client list. We offer scientific leadership and customized solutions for our clients’ unique research challenges,” says Kendall.

A recent estimate put the global microbiome sequencing services market at over USD $500 million in 2016. With microbiome knowledge in the nascent phase, significant investment potential exists in this burgeoning market environment.

Dr. Tony Brooks, Chief Financial Officer and Vice President, Entrepreneurship and Commercialization at Genome BC, says, “Our I² financing of $750,000 combined with MBI’s recent round of equity funding will be used to accelerate MBI’s sales and marketing activities, make new hires, the buildout of a new CLIA-certified lab facility, and the development and launch of new services and personal health test products.”

Genome BC’s I² Fund provides commercialization support for companies developing innovative life science technologies that address biological challenges in key economic sectors in BC: Agriculture, Energy and Mining, Environment, Fisheries and Aquaculture, Forestry, and Human Health. The I² Fund also supports digital health and other technologies that further move precision medicine into clinical practice. I² funding is repayable and is allocated to promising technologies (products, processes or services) at the early stages of commercial development. The Fund aims to provide risk capital that is concurrently matched by other public or private funding sources.

See this press release online here.

Microbiome Insights sponsors inaugural Microbiome Human Nutrition Summit in Boston

Microbiome Insights Inc. was an exhibitor and sponsor for the first Microbiome Human Nutrition Summit, held Nov. 15-16, 2017 in Boston. The event was focused on helping prebiotic, probiotic, food, and pharmaceutical manufacturers translate microbiome research into next-generation food and nutrition products that improve human health.

The conference covered a wide range of topics in the areas of microbiome, health, and nutrition, including establishment of cause and effect in the microbiome, control of the gut through dietary modifications, and the relevance of infant microbiome in infant health and nutrition.

Notable speakers included Dr. Chris Damman, a program officer at the Bill and Melinda Gates Foundation, who discussed how gut health impacts health care interventions in developing countries; and Dr. David Kyle, CEO of Evolve Biosystems Inc, who spoke about the role of Bifidobacterium infantis in infant nutrition.

At Understand Your Genome event, Microbiome Insights participates in latest discussions on genome sequencing for disease prediction and prevention

Microbiome Insights Inc. was an exhibitor and sponsor at the third annual Boston Understand Your Genome conference, held on Nov. 14, 2017. The all-day event centered on the progress and promise of genomic medicine and the issues regarding sequencing the genomes of healthy individuals for disease prediction and prevention.

The conference topics included sequencing and informatics in clinical care, precision health, and understanding the basics of genetics and genomics. Among the event’s speakers were Dr. Hannah Valantine, Chief Officer for Scientific Workforce Diversity at the National Institutes of Health, who discussed racial disparities in organ transplant outcomes and diversity issues in genomics; and Dr. Calum MacRae, Chief of Cardiology at Brigham and Women’s Hospital in Boston, who spoke about the need for a robust global phenotype effort to replace the outdated diagnostic guidelines used today.

All conference participants were also offered the opportunity to have their genome sequenced and analyzed for genes and variants associated with adult-onset conditions, carrier status, and drug response.

At #ASHG17, Microbiome Insights offers a chance to win 50 complimentary samples for amplicon sequencing

OCTOBER 21, 2017 – The Microbiome Insights team travelled to Orlando on October 17th to 21st, 2017, to attend the American Society of Human Genetics 2017 meeting (ASHG 2017) as exhibitors. Visitors to the company booth could enter their card into a draw for complimentary amplicon sequencing of 50 samples, as they discussed with our team the benefits of combining genetics/genomics with microbiome analysis.

Dr. Athena Starlard-Davenport of the Department of Genetics, Genomics and Informatics at the University of Tennessee Health Science Center was the winner of the draw for free amplicon sequencing of 50 samples.

Microbiome Insights recognized in BCIC-New Ventures Competition: Growth shows demand for capitalizing on potential of microbiome

October 4, 2017 (GLOBE NEWSWIRE) – As researchers and companies around the world increasingly recognize the importance of the microbiome, they face a critical gap in expertise, according to one Vancouver biotechnology startup.

Microbiome Insights, Inc., which conducts testing and bioinformatics on microbial communities for applications ranging from human health and disease to beauty products and agriculture, aims to help their clients address this expertise gap and innovate more quickly.

Last week, Microbiome Insights’ growth and momentum was recognized with a second place win in the 2017 British Columbia Innovation Council-New Ventures Competition, out of a field of 166 companies. The company also took home the Centre for Drug Research and Development Life Sciences award.

“The microbiome is one of the fastest growing areas in life sciences,” says Malcolm Kendall, Microbiome Insights’ CEO. “Microbiome science is changing the direction of numerous large industries like healthcare, food, cosmetics and agriculture, and can add significant value to products. Our success in this competition highlights the bright future for microbiome testing and expertise.”

A panel of judges made up of industry experts, venture capitalists, and successful entrepreneurs determined that the company was primed to succeed as a business venture in the current market environment. The company is on a run rate to grow its revenue over 400 percent this year.

“A major theme in research today is a growing appreciation of the importance of microbial communities, or microbiomes, and the imperative to better understand these communities,” says University of British Columbia professor Dr. Bill Mohn, who co-founded the company with his colleague, Dr. Brett Finlay. “These highly complex communities are critical for human health, environmental quality and industrial processes.  Consequently, there is a real need for expertise in designing and conducting microbiome studies.”

Kendall adds, “Our testing services help researchers and companies innovate and accelerate the development of products so they can remain competitive as microbiome science advances and impacts their industry.”

Reports indicate advances in microbiome science offer tremendous potential for medical, environmental and economic benefits. Analysis of the human microbiome may yield new approaches to diagnose and treat many chronic diseases, while understanding and managing environmental microbiomes may improve productivity and sustainability of agriculture and diverse resource industries, such as forestry, mining and aquaculture.

About the BCIC-New Ventures Competition

New Ventures BC (NVBC) is a not-for-profit that promotes entrepreneurship through innovation. NVBC runs the annual BCIC-New Ventures Competition, offering education, coaching, and $300,000+ in prizes to B.C. startups. The NVBC Venture Acceleration programs also provide training and mentorship for early-stage tech companies. Over the past 17 years NVBC competition winners have gone on to create 2,700 jobs and raise $300 million in financing.

Learn more: newventuresbc.com

See this press release online here.

See the Microbiome Insights video here.

Microbiome Insights’ co-founders participate in Personalized Medicine Initiative webinar

MARCH 29, 2017 – Two of Microbiome Insights’ co-founders, CEO Malcolm Kendall and Dr. Bill Mohn, were key speakers this week in a webinar organized by British Columbia’s Personalized Medicine Initiative (PMI). The webinar, open to participants across North America, focused on how microbiome research will contribute to personalized medicine as our knowledge advances.

“Microbiome Insights is proud to be part of a dynamic community working toward a more personalized approach to medical care, as the microbiome shows great promise for helping this field move forward,” says Kendall. The company, founded under the umbrella of the Personalized Medicine Initiative, enables both academic and industrial clients to seamlessly complete their microbiome research.

The PMI is a broad organization of personalized medicine stakeholders and resources in British Columbia; its mission is to introduce technologies enabling personalized (molecularly-based) medicine to the front lines of healthcare, facilitating a more efficient medical system. The PMI also serves as an educational and information resource for residents and medical practitioners. The organization is led by a Board of Directors that includes Pieter Cullis (Chair), David Huntsman, Bruce McManus, Martin Dawes and James Russell, with input from an Advisory Committee that represents a cross-section of interests relating to healthcare, science, technology, ethics, and health policy.

Microbiome Insights Tops BC’s 2017 Life Science Emerging Rocket List

MARCH 3, 2017 – After becoming one of nine companies included on the 2017 Life Science Emerging Rocket List in British Columbia, Microbiome Insights has been honoured with the program’s Ready to Rocket award in the Life Science division.

The award is part of the Ready to Rocket business recognition program in British Columbia’s tech sector, which showcases revenue growth leaders in the province.

Microbiome Insights Included on CB Insights’ List of 20+ Startups Attacking the Human Microbiome

DECEMBER, 2016 – Microbiome Insights, Inc. was recently included on a list of microbiome-focused startup companies assembled by the venture capital database CB Insights. The platform identified the most well-funded private companies targeting the microbiome and mapped them according to the category in which they operate. Microbiome Insights appeared in the “genomics” category as a company focused on microbiome analysis across a range of applications.

Microbiome Insights Establishes Scientific Advisory Board

September 23, 2015 – Microbiome Insights, Inc. is pleased to announce today the formation of its inaugural Scientific Advisory Board (SAB). The board is comprised of leaders in the field whose work has led to significant breakthroughs in both basic and clinical understandings of the microbiome.

The inaugural members are:

  • Ken Croitoru, MD, gastroenterologist at Mount Sinai Hospital in Toronto, Canada. His research focuses on the fundamental mechanisms underlying intestinal inflammation, particularly as it relates to inflammatory bowel disease. He is the project leader of the GEM Project, a study that explores the genetic, environmental, and microbial factors that lead to Crohn’s disease.
  • Curtis Huttenhower, PhD, Associate Professor of computation biology and bioinformatics at the Harvard T.H. Chan School of Public Health. His research leverages computational methods, including machine learning, to investigate microbial community function and human health. He and his lab have worked extensively on the NIH Human Microbiome Project.
  • Janet Jansson, PhD, Division Director of Biological Sciences at the Pacific Northwest National Laboratory in Richland, Washington. She has over 30 years’ experience in microbial ecology with specific expertise in the use of molecular approaches to study complex microbial communities in the environment and human gut.
  • Samuel Miller, MD, Professor of medicine, microbiology, immunology, and genome sciences at the University of Washington. His research focuses on how bacteria cause disease and interact with host cells. He is also Director of the NIAID Northwest Research Center for Excellence in Biodefense and Emerging Infectious Diseases.

The board, whose mission is to provide scientific, strategic, and technical guidance for Microbiome Insights’ service business and other projects, is co-chaired by founders Brett Finlay, PhD, and Bill Mohn, PhD.

“We are thrilled to have assembled this world class team to guide us,” said Malcolm Kendall, CEO of Microbiome Insights. “This Scientific Advisory Board draws upon the best and brightest in microbial ecology, bioinformatics and medicine, and their collective breadth and depth of experience will be crucial to all aspects of our business.”

Microbiome Insights, Inc. is a Vancouver-based company that provides state-of-the-art testing and analysis of the microbiome—the complex communities of bacteria, viruses, and fungi that inhabit humans, animals, plants, and the environment. It provides end-to-end service for researchers in academia and industry who wish to incorporate microbiome research in their studies across a range of human, animal, agricultural, and environmental applications.

Life sciences industry leaders form Microbiome Insights’ inaugural board of directors

MAY 30, 2015 — Microbiome Insights, Inc. is pleased to announce the members of its inaugural Board of Directors (BOD). The members bring with them a wealth of knowledge from the global life sciences industry. Each one has achieved success in academic and/or industry roles and has contributed to groundbreaking advancements in their respective disciplines.

The members are:

Pieter Cullis, PhD, Director at the Life Sciences Institute, University of British Columbia.

Dr. Pieter Cullis brings decades of experience in research and business. He is, along with his colleagues in academia, responsible for many fundamental advances in the field of lipid nanoparticle systems for intravenous delivery of small molecule and macromolecular drugs. This work has led to three products which have been approved by regulatory agencies in the US and Europe, and a further five that have finished Phase 1 trials. Outside of his academic achievements, Dr. Cullis co-founded several biotech companies and has received many distinguished awards, including election to the Royal Society of Canada in 2004.

Brad Popovich, PhD, former Chief Scientific Officer at Genome BC

Dr. Brad Popovich has long been involved with Genome BC, serving on its Board of Directors from 2006-2011 and acting as the Chair for the Scientific Committee from 2008-2010. Alongside his current roles with Genome BC he serves as Chairman for the Genetic Information Management Systems and Director of the Centre for Drug Research and Development Ventures and Centre for Drug Development. His genetics expertise is in genetic counselling; he graduated with Masters degrees in genetic counselling and biochemical genetics, and was awarded a PhD in molecular genetics from McGill University. He also received postdoctoral training and a clinical fellowship in the lab of Nobel Laureate Oliver Smithies. Throughout his career, Dr. Popvich has held many titles as Director, Vice-President, and CEO of numerous companies and academic institutions—including founder and director of the Molecular Diagnostics Laboratory at Oregon Health Sciences University and founding member of the Oregon DNA Forensic Experts Panel.

Mike Fannon, Founder and CEO of BioIT Solutions.

Mike Fannon currently advises new biotechnology firms in the areas of information technology and customer relationship management, business strategy, and laboratory automation. He is CEO of BioIT solutions, a leading company specializing in advanced computational, workflow, and data-management systems for clinical diagnostics, drug development, and biotechnology research. He was the chief architect of BioIT’s innovative 1Platform4 software and was the former Vice President and Chief Information Officer at Human Genome Sciences, where he and his team developed computerized solutions to manage Human Genome Sciences’ R&D functions, high-volume labs, product development, and clinical trials. Mr. Fannon holds an MBA in Operations Analysis from American University and a Bachelors degree in Physics from Rollins College.

Microbiome Insights Officially Incorporates

February 12, 2015 – Microbiome Insights, Inc. announced its official incorporation today as a company providing end-to-end services in microbiome analysis. These services, which include experimental design, sample testing, and bioinformatic analysis, are aimed at researchers in both academia and industry seeking to conduct microbiome studies.

Based out of Vancouver, Canada, Microbiome Insights is a spinout from both the Life Science Institute and the Personalized Medicine Initiative at the University of British Columbia (UBC). Drawing on the decades of experience of its scientific co-founders, professors Dr. B. Brett Finlay and Dr. Bill Mohn, Microbiome Insights fills the expertise gap that currently exists between expanding interest in the field and successful studies and products.

The study of microbiomes—complex ecosystems of microorganisms including bacteria, viruses and fungi—is one of the fastest growing areas in life sciences research. The functions and interactions of these communities have a profound impact on human, animal, and environmental health. While more and more groups are recognizing the value of adding microbiome analyses to their work, many lack the technical know-how to design and carry out such studies and interpret the results.

“Our goal is to provide researchers with a resource for expert microbiome analysis,” says Malcolm Kendall, co-founder and CEO. “Along with my fellow founders, Brett Finlay and Bill Mohn, I feel the company is uniquely positioned to offer highly specialized services to a broad market, helping drive innovation.”

Microbiome Insights’ services centre on extraction, quality control, analytics and bioinformatics—providing clients with publication-quality data and state-of-the-art analysis. The company’s flexible end-to-end service model also includes pre-study consultation, data consultation, and advanced reporting.

Microbiome Insights will seek partnerships with other organizations to further understandings of microbial communities and to co-develop new products and services.